Meridian Bioscience, Inc.
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates thro…
Medical - Diagnostics & Research
US, Cincinnati [HQ]
Insiders
Transactions
Track non-derivative insider transactions.
i = Indirect Ownership
d = Direct Ownership
cs = Common Stock
| Reported Owner(s) | Position Now | Transaction Date | Type | Position Change | Extra | ||
|---|---|---|---|---|---|---|---|
|
$0
d
cs
10% Holder
|
01/31/23 |
D
|
16,424 x $0 = $0 |
Footnotes
#1 The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
|
|||
|
$0
d
cs
10% Holder
|
01/31/23 |
D
|
27,449 x $0 = $0 |
Footnotes
#1 The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
|
|||
|
$0
d
cs
10% Holder
|
01/31/23 |
D
|
21,724 x $0 = $0 |
Footnotes
#1 The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
|
|||
|
$0
d
cs
10% Holder
|
01/31/23 |
D
|
17,290 x $0 = $0 |
Footnotes
#1 The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
|
|||
|
$0
d
cs
10% Holder
|
01/31/23 |
D
|
10,274 x $0 = $0 |
Footnotes
#1 The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
|
|||
Get PRO Today
With PRO you will unlock 62 more insider transactions for Meridian Bioscience, Inc.
Statistics
Sample Size: 67 Transactions
Sale (S)
159,603 Shares
7.46%
Buy (P)
4,028 Shares
1.49%
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Anderson James M. Director
- Baldasare Bryan T Exec VP & CFO
- Bihl Anthony P Iii Director
- Ellingwood Dwight E Director
- Kenny John P. Director
- Kitzmiller Andrew S. Executive Vice President & CFO
- Mcilwraith John Director
- Phillips David Director
- Rice John Mccune Jr. Director
- Sazdanoff Catherine Director
- Serafini-Lamanna Tony Executive VP-Diagnostics
- Smith Julie Diana Sr VP, Controller, PAO
- Weltzien Lourdes Executive VP, Life Science
- Williams Felicia Director
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Anderson James M. Director
- Baldasare Bryan T Exec VP & CFO
- Bihl Anthony P Iii Director
- Ellingwood Dwight E Director
- Kenny John P. Director
- Kitzmiller Andrew S. Executive Vice President & CFO
- Mcilwraith John Director
- Phillips David Director
- Rice John Mccune Jr. Director
- Sazdanoff Catherine Director
- Serafini-Lamanna Tony Executive VP-Diagnostics
- Smith Julie Diana Sr VP, Controller, PAO
- Weltzien Lourdes Executive VP, Life Science
- Williams Felicia Director